Reference is made to previous call for extraordinary general meeting Monday 16 April 2012, and the announcement regarding the establishment of underwriting syndicate for the rights issue.

The Board of Directors has decided the further details of the proposed rights issue within the framework of the notice of the general meeting. It is proposed that, in the rights issue, a minimum of 400 million and a maximum of 750 million new shares are offered at a subscription price of NOK 0.02, rising gross proceeds of minimum NOK 8 million, maximum NOK 15 million, with pre-emptive subscription rights for existing shareholders as per the date of the general meeting. In relation to the rights issue, an underwriting syndicate guaranteeing subscription of NOK 8,140,000 worth of shares has been established, in which, among others, members of the board and the management of the company is participating.
 
Participators in the underwriting syndicate are also proposed to receive one warrant per share guaranteed for. Each warrant will give the right to require the issuance of one share as a subscription price of NOK 0.02.
 
The rights issue is conditional of confirmation in the extraordinary general meeting.
 
Certain of the underwriters have also agreed to make a bridge loan available for the company in the total amount of NOK 3,950,000. The bridge loan will be converted to shares and/or repaid in relation to the completion of the rights issue.
 
For further information, please contact:
CEO Mårten Wigstøl, Phone: +47 911 65775
 
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNAfrom difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in
Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden and in Atlanta (GA), USA. The group has today 29.15 man-labour years. NorDiag is listed on the Oslo Stock Exchange with ticker NORD.
 
Read the notice in Norwegian here.